|
|||||
|
|
| Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter
|
| Ticker | Owner | Relationship | Date | Transaction | Cost |
#Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MYO | Harry Kovelman | Officer | Jun 28 '25 | Proposed Sale | 2.19 | 13,054 | 28,588 | Jun 30 08:04 PM | |
| MYO | Harry Kovelman | Officer | Jun 06 '25 | Proposed Sale | 2.97 | 5,743 | 17,057 | Jun 06 07:08 PM | |
| MYO | Kovelman Harry | Chief Medical Officer | Mar 12 '25 | Sale | 5.50 | 30,000 | 165,018 | 97,973 | Mar 13 04:41 PM |
| MYO | Harry Kovelman | Officer | Mar 13 '25 | Proposed Sale | 5.22 | 1,496 | 7,809 | Mar 13 04:28 PM | |
| MYO | HARRY KOVELMAN | Officer | Mar 12 '25 | Proposed Sale | 5.50 | 30,000 | 165,015 | Mar 12 04:59 PM | |
| MYO | Kovelman Harry | Chief Medical Officer | Jun 09 '24 | Option Exercise | 0.00 | 1,235 | 0 | 124,549 | Jan 24 05:02 PM |
| MYO | Harry Kovelman | Officer | Nov 04 '24 | Proposed Sale | 3.70 | 121 | 448 | Nov 04 03:19 PM | |
| MYO | Harry Kovelman | Officer | Oct 03 '24 | Proposed Sale | 3.86 | 121 | 467 | Oct 03 12:54 PM | |
| MYO | Kovelman Harry | Chief Medical Officer | Sep 05 '24 | Sale | 3.76 | 6,700 | 25,183 | 123,556 | Sep 09 04:04 PM |
| MYO | Kovelman Harry | Chief Medical Officer | Sep 03 '24 | Sale | 4.01 | 2,029 | 8,140 | 130,395 | Sep 05 08:27 AM |
| MYO | Harry Kovelman | Officer | Sep 04 '24 | Proposed Sale | 3.89 | 139 | 541 | Sep 04 06:26 PM | |
| MYO | Harry Kovelman | Officer | Sep 03 '24 | Proposed Sale | 4.00 | 18,500 | 74,000 | Sep 03 05:55 PM | |
| MYO | Harry Kovelman | Officer | Aug 05 '24 | Proposed Sale | 3.96 | 128 | 507 | Aug 05 11:53 AM | |
| MYO | Kovelman Harry | Chief Medical Officer | May 15 '24 | Sale | 3.69 | 35,426 | 130,839 | 98,009 | May 17 04:57 PM |
| MYO | Kovelman Harry | Chief Medical Officer | Aug 29 '23 | Buy | 0.60 | 8,333 | 5,000 | 149,556 | Aug 30 05:00 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite